Disclosure under regulation 30

TAVEXIA LIFECARE LIMITED (FORMERLY SATTVA SUKUN LIFECARE LIMITED) CIN: L27509MH1980PLC329224 Date: 12/10/2026 BSE Limited Department of Corporate Services, Ground Floor, P.J. Tower, Dalal Street, Mumbai-400 001 Scrip ID – TAVEXIA. Scrip Code: 539519 Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Strategic Business Expansion and Proposed Acquisition of Controlling Stake in Meyonex Pharmaceuticals Limited Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that in a decisive move to align its corporate identity with high-growth business verticals, Tavexia Lifecare Limited (formerly known as Sattva Sukun Lifecare Limited; BSE Scrip Code: 539519) has unveiled a refreshed corporate brand and an ambitious roadmap for the future. The rebranding signifies much more than a cosmetic update, it represents a structured realignment towards capitalizing on emerging opportunities across the pharmaceutical, wellness, and lifecare landscape. Expanding the Horizons: Broadening into High-Margin Segments Demonstrating foresight and adaptability, the company has altered its Main Object Clause under its Memorandum of Association. This strategic revision opens significant avenues across: ● Active Pharmaceutical Ingredients (APIs) & Bulk Drugs: Expanding into core building blocks of global medicine. ● Finished Dosage Forms & Formulations: Moving up the value chain with tablets, capsules, injectables, and advanced delivery formats. ● High-Growth CDMO & CRAMS Services: Venturing into Contract Research and Manufacturing Services (CRAMS) as well as Contract Development and Manufacturing Organizations (CDMO), catering to rising domestic and international demand. ● Nutraceuticals & Biotechnology: Tapping into consumer-driven preventive healthcare and life sciences. Transformational Move: Strategic Controlling Stake in Meyonex Pharmaceuticals Marking a major milestone in its growth strategy, the Board of Directors approved the acquisition of a Regd Office: Plot No. 2B/1, Ground Floor, Kandivali Cooperative Industrial Estate Ltd., Hindustan Naka, Kandivali (West), Mumbai – 400067 Tel: +91-22-2868 4491 | Email: info@mayukh.co.in & sattvasukunlifecarelimited@gmail.com| Website: www.mayukh.co.in, https://sattvasukun.co.in/ , www.tavexia.com TAVEXIA LIFECARE LIMITED (FORMERLY SATTVA SUKUN LIFECARE LIMITED) CIN: L27509MH1980PLC329224 60% controlling equity stake in Meyonex Pharmaceuticals Limited through a cash subscription of 2,09,97,180 fresh equity shares valued at ₹67.19 Crore (at an issue price of ₹32 per share). Key highlights of this acquisition include: ● Immediate Operational Foothold: Meyonex brings established manufacturing and commercial operations based in MIDC Tarapur, Maharashtra, delivering direct access to high-demand pharma product lines. ● Significant Synergies: The acquisition provides an immediate growth runway, enabling Tavexia to scale its revenue baseline and leverage operational efficiencies. ● Well-Capitalized Roadmap: To finance this expansion, the management has initiated plans for strategic fund-raising through permissible equity or convertible instruments, maintaining capital discipline while backing accretive growth. Sector Tailwinds: Why the Future Looks Bright The pharmaceutical and lifecare sector remains one of the most resilient, high-margin sectors globally. With sustained tailwinds supporting domestic manufacturing, global supply-chain diversification ("China+1"), and escalating demand for specialized generic formulations and contract manufacturing, well-positioned niche players have immense scope for value creation. By pivoting decisively into contract manufacturing, APIs, and scalable pharma assets, Tavexia Lifecare’s forward-looking management is building a resilient platform positioned to unlock substantial long-term value. Please take the same on your record and acknowledge the receipt of the same Thanking You, Yours Faithfully For Tavexia Lifecare Limited (Formerly known as: Sattva Sukun Lifecare Limited) Poonam Rani Company Secretary Regd Office: Plot No. 2B/1, Ground Floor, Kandivali Cooperative Industrial Estate Ltd., Hindustan Naka, Kandivali (West), Mumbai – 400067 Tel: +91-22-2868 4491 | Email: info@mayukh.co.in & sattvasukunlifecarelimited@gmail.com| Website: www.mayukh.co.in, https://sattvasukun.co.in/ , www.tavexia.com